Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics.
11 affiliations
- 1National Center for Drug Research and Evaluation, National Institute of Health (ISS), 00161 Rome, Italy.
- 2Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
- 3Gastroenterology and Endoscopy Unit, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
- 4Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, ENETS Center of Excellence, Sapienza University of Rome, 00189 Rome, Italy.
- 5Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, 00189 Rome, Italy.
- 6Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy.
- 7U.O.C. Diagnostic Imaging, PTV Policlinico "Tor Vergata" University, 00133 Rome, Italy.
- 8Nuclear Medicine Unit, University Hospital Sant'Andrea, 00189 Rome, Italy.
- 9Medical Oncology Unit, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
- 10Department of Clinical Medicine and Surgery, Section of Endocrinology, Diabetology, Andrology and Nutrition, University of Naples Federico II, 80138 Naples, Italy.
- 11UNESCO Chair for Health Education and Sustainable Development, University of Naples Federico II, 80138 Naples, Italy.
Abstract
Background: Pulmonary neuroendocrine tumors (lung NETs) comprise a biologically heterogeneous group of neoplasms ranging from indolent typical carcinoids to more aggressive atypical carcinoids. Accurate characterization of tumor biology is essential for optimizing staging, prognostic stratification, and treatment selection. Beyond conventional cross-sectional imaging, functional imaging and emerging quantitative imaging techniques are progressively redefining the diagnostic pathway. Methods: We performed a comprehensive narrative review of the current evidence regarding conventional radiological imaging, somatostatin receptor (SSTR) PET/CT, ¹⁸F-FDG PET/CT, dual-tracer imaging, and radiomics in lung NETs, integrating recent international recommendations from ENETS, ESMO, AIOM, and other major societies. Results: Contrast-enhanced CT remains the cornerstone of anatomical staging, whereas ⁶⁸Ga-labelled somatostatin analogue (SSA) PET/CT provides highly sensitive assessment of receptor expression and patient eligibility for somatostatin analogue therapy and peptide receptor radionuclide therapy (PRRT). Conversely, ¹⁸F-FDG PET/CT identifies metabolically active and biologically aggressive disease, particularly in atypical carcinoids and tumors showing dedifferentiation. Increasing evidence supports the complementary role of dual-tracer PET/CT for non-invasive characterization of tumor heterogeneity, prognostic stratification, and treatment planning. Radiomics further expands this paradigm by extracting quantitative imaging biomarkers that may improve histological prediction, recurrence risk assessment, and individualized management. Although promising, radiomics remains limited by methodological heterogeneity and the lack of prospective validation. Conclusions: The integration of conventional imaging, molecular imaging, and quantitative radiomics supports a shift from lesion detection toward biologically driven precision imaging. Future prospective multicenter studies incorporating imaging biomarkers, artificial intelligence, and clinical-pathological variables may further support personalized management of patients with lung NETs.
Related
- AI-bioinformatics synergy for precision medicine in brain diseases: integrating radiomics and multi-omics data.
- A primary care-oriented framework for osteoporosis prediction: integrating multi-algorithm feature selection and machine learning model benchmarking.
- Automated radiomics pipeline integrating TotalSpineSeg for Pfirrmann grading of lumbar disc degeneration with SHAP-based interpretability
- Nomogram models integrating multiregion radiomics, quantitative computed tomography, and clinical indicators for distinguishing connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis and improving the prediction of gender-age-physiology stage
- Pharmacy Education in Korea: Transition to Clinically Oriented Education and the Establishment of the National Specialist Pharmacist System as a Foundation for Advanced Pharmacy Practice
BibTeX
@article{salvia2026toward,
title = {{Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics.}},
author = {Anna La Salvia and Roberta Elisa Rossi and Piero Paravani and Enrico D'Ippolito and Arianna Gagliardi and Giorgia Maria Granese and Rosaria Meucci and Luciano Carideo and Davide Campana and Alberto Signore and Annamaria Colao and Antongiulio Faggiano and Daniela Prosperi and Nike Group},
journal = {Cancers},
year = {2026},
month = sep,
doi = {10.3390/cancers18193111},
url = {https://europepmc.org/article/MED/42882806},
note = {CC BY},
}
RIS
TY - JOUR
TI - Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics.
AU - Anna La Salvia
AU - Roberta Elisa Rossi
AU - Piero Paravani
AU - Enrico D'Ippolito
AU - Arianna Gagliardi
AU - Giorgia Maria Granese
AU - Rosaria Meucci
AU - Luciano Carideo
AU - Davide Campana
AU - Alberto Signore
AU - Annamaria Colao
AU - Antongiulio Faggiano
AU - Daniela Prosperi
AU - Nike Group
PY - 2026
DA - 2026/09/25
JO - Cancers
DO - 10.3390/cancers18193111
UR - https://europepmc.org/article/MED/42882806
AB - Background: Pulmonary neuroendocrine tumors (lung NETs) comprise a biologically heterogeneous group of neoplasms ranging from indolent typical carcinoids to more aggressive atypical carcinoids. Accurate characterization of tumor biology is essential for optimizing staging, prognostic stratification, and treatment selection. Beyond conventional cross-sectional imaging, functional imaging and emerging quantitative imaging techniques are progressively redefining the diagnostic pathway. Methods: We performed a comprehensive narrative review of the current evidence regarding conventional radiological imaging, somatostatin receptor (SSTR) PET/CT, ¹⁸F-FDG PET/CT, dual-tracer imaging, and radiomics in lung NETs, integrating recent international recommendations from ENETS, ESMO, AIOM, and other major societies. Results: Contrast-enhanced CT remains the cornerstone of anatomical staging, whereas ⁶⁸Ga-labelled somatostatin analogue (SSA) PET/CT provides highly sensitive assessment of receptor expression and patient eligibility for somatostatin analogue therapy and peptide receptor radionuclide therapy (PRRT). Conversely, ¹⁸F-FDG PET/CT identifies metabolically active and biologically aggressive disease, particularly in atypical carcinoids and tumors showing dedifferentiation. Increasing evidence supports the complementary role of dual-tracer PET/CT for non-invasive characterization of tumor heterogeneity, prognostic stratification, and treatment planning. Radiomics further expands this paradigm by extracting quantitative imaging biomarkers that may improve histological prediction, recurrence risk assessment, and individualized management. Although promising, radiomics remains limited by methodological heterogeneity and the lack of prospective validation. Conclusions: The integration of conventional imaging, molecular imaging, and quantitative radiomics supports a shift from lesion detection toward biologically driven precision imaging. Future prospective multicenter studies incorporating imaging biomarkers, artificial intelligence, and clinical-pathological variables may further support personalized management of patients with lung NETs.
SN - 2072-6694
ER -